返回搜索
正在招募II 期编号 NCT03297606

Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)

报名条件(概要)

  • 年龄:18 Years – 不限
  • 性别:不限
  • 健康志愿者:不接受

完整入排标准请以官方页面为准。

开展国家/地区

Canada

药品与企业信息

Olaparib药物

300mg taken twice daily

Dasatinib药物

100mg administered orally once daily

Nivolumab plus Ipilimumab药物

* Combination Phase - 3mg/kg nivolumab administered as an intravenous infusion over 30 minutes every 3 weeks for the first 4 doses in combination with ipilmumab 1mg/kg administered intravenously over 30 minutes, followed by the single-agent phase. * Single-Agent Phase - 480mg nivolumab administered as an intravenous infusion over 30 minutes every 4 weeks.

Axitinib药物

5mg orally twice daily

Bosutinib药物

500mg orally once daily

250mg orally twice daily

125mg orally once daily for 21 consecutive days followed by 7 days off treatment to comprise a complete cycle of 28 days

Sunitinib药物

50mg orally once daily on a schedule of 4 weeks on treatment followed by 2 weeks off

研发企业

Canadian Cancer Trials Group研究网络

试验官方登记的主要申办方;研究机构申办时会显示相应机构名称。

生产企业

Dasatinib

Prasco Laboratories

合作机构

  • AstraZeneca企业
  • Bristol-Myers Squibb企业
  • Hoffmann-La Roche企业
  • Pfizer企业
  • Seagen Inc.企业

研发企业与生产企业可能不是同一家。研究阶段药品可能尚未公布生产企业;生产企业仅取自美国上市原研药说明书所列企业(不含仿制药),不作推测;仅在其他国家上市的药品暂无法显示。

研究简介(原文)

Cancer drugs which target the effects of abnormal gene changes are called 'targeted therapies'. This study, called PM.1 or CAPTUR, will include some targeted therapies that are currently available. The purpose of this study is to find out what are the effects on a patient and their cancer when they are given a targeted therapy drug that is specific to an abnormal gene change in their cancer.

适应症

Lymphoma, Non-HodgkinMultiple MyelomaAdvanced Solid Tumors

主动联系研究团队

这项试验目前在中国大陆没有研究中心

这种情况下,直接发"入组咨询"往往会被回复"您所在地区没有中心"。更有效的做法是申请同情用药/扩展准入(由主治医生一同提出),或询问能否到最近的境外中心参加。下面已为您切换到对应的信件版本。

查看完整申请路径与成功率说明 →

总联系人(申办方/研究总部)

研究中心联系方式

  • Cross Cancer InstituteEdmonton,Alberta,Canada
  • BCCA - KelownaKelowna,British Columbia,Canada
  • BCCA - VancouverVancouver,British Columbia,Canada
  • London Health Sciences Centre Research Inc.London,Ontario,Canada
  • Ottawa Hospital Research InstituteOttawa,Ontario,Canada
  • University Health NetworkToronto,Ontario,Canada

问自己是否符合条件、如何预筛

我的病情档案

管理档案

档案只保存在您自己的浏览器里,不会上传,任何人(包括本站)都看不到。

英文版(发给研究团队)

Dear Study Team,

I am a patient in China and I am interested in participating in your clinical trial:

Study Title: Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)
ClinicalTrials.gov Identifier: NCT03297606
Sponsor: Canadian Cancer Trials Group
Investigational product: Olaparib, Dasatinib, Nivolumab plus Ipilimumab, Axitinib, Bosutinib

About me:
- Age: (please fill in)
- Sex: (please fill in)
- Confirmed diagnosis and stage: (please fill in)
- Biomarkers / genetic testing: not available
- Prior and current treatments: (please fill in)
- Performance status (ECOG): not assessed
- Current location: China
- Travel ability: (please fill in)

Could you please let me know:
1. Whether I might be eligible for this study;
2. Which site would be closest and most practical for me, and whether remote pre-screening is possible;
3. What documents (medical records, pathology or imaging reports, recent labs) I should prepare for pre-screening.

I can provide English translations of my medical records. Thank you very much for your time and help.

Kind regards,
(your name)
(your email / phone with country code)

中文对照(供您核对)

尊敬的研究团队:

我是一位来自中国的患者,希望咨询参加以下临床试验的可能:

研究名称:Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)
试验编号:NCT03297606
申办方:Canadian Cancer Trials Group
研究药物:Olaparib、Dasatinib、Nivolumab plus Ipilimumab、Axitinib、Bosutinib

我的基本情况:
- 年龄:(请填写)
- 性别:(请填写)
- 确诊疾病与分期:(请填写)
- 基因/标志物检测:暂无
- 既往及当前治疗:(请填写)
- 体能状态(ECOG):未评估
- 目前所在城市:中国
- 可前往范围:(请填写)

想请教三个问题:
1. 我是否可能符合本研究的入组标准?
2. 哪个中心对我最方便可行?能否远程预筛?
3. 预筛需要准备哪些资料(病历、病理、影像、近期化验)?

我可以提供英文翻译版病历。感谢您的时间与帮助。

顺祝安康
(您的姓名)
(您的邮箱/带国际区号的电话)
用邮件客户端发送给 jdancey@ctg.queensu.ca

提示:请与主治医生一起发信——由医生署名的申请,回复率远高于患者单独发信。首封邮件不要附身份证号等敏感信息。研究团队通常在 3–10 个工作日内回复,两周无回音可礼貌追问一次。

下一步怎么做?

  1. 把本页信息带给您的主治医生,评估是否适合参加。
  2. 点击下方按钮打开官方注册页,查看研究中心联系方式。
  3. 直接联系研究团队咨询报名事宜(通常有中文同声翻译服务可协助沟通)。
在 ClinicalTrials.gov 查看官方页面